等待开盘 11-26 09:30:00 美东时间
+0.620
+15.62%
今日重点评级关注:HC Wainwright & Co.:维持BiomX"买入"评级,目标价从15美元升至26美元;Clear Street:维持Diversified Energy"买入"评级,目标价从23美元升至25美元
今天 10:07
Citizens analyst Jason N. Butler initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Market Outperform rating and announces Price Target of $19.
11-25 21:41
Achieve Life Sciences (($ACHV)) has held its Q3 earnings call. Read on for the ...
11-07 08:56
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced
11-03 21:41
Achieve Life Sciences appoints Erik Atkisson as Chief Legal Officer. With over 25 years of experience in the biopharmaceutical industry, Atkisson will oversee legal strategy, corporate governance, compliance, and risk management. The company is advancing cytisinicline, a treatment for nicotine dependence, through regulatory review with an expected PDUFA date of June 20, 2026. Cytisinicline has shown promise in Phase 3 studies for smoking cessatio...
10-20 12:30
Shares of CSX Corp (NASDAQ:CSX) rose sharply in pre-market trading after the co...
10-17 17:55
Gainers Artiva Biotherapeutics (NASDAQ:ARTV) shares increased by 96.8% to $5.45...
10-17 05:06
Achieve Life Sciences announced that its board of directors approved stock option grants to purchase 161,000 shares of its common stock for five new employees under the 2024 Equity Inducement Plan. The stock options, exercisable at the closing price on October 1, 2025, have a 10-year term and vest 25% after one year of employment and the remaining 75% in monthly installments over three years. Achieve is a late-stage pharmaceutical company develop...
10-02 20:01
Achieve Life Sciences announced new data in *Thorax* showing cytisinicline significantly improved smoking quit rates compared to placebo in adults with and without COPD. The post hoc analysis of the ORCA-2 and ORCA-3 trials, involving over 1,600 participants, demonstrated cytisinicline's effectiveness and safety for COPD patients, a high-risk group. Cytisinicline achieved comparable quit rates for COPD and non-COPD subgroups, with a favorable saf...
09-22 12:30